Reacta Healthcare Ltd, a UK-based developer of food allergy diagnostic products, announced on Thursday the appointment of Richard Nagle as chair of its board of directors.
Nagle has more than 30 years of experience in the pharmaceutical, biotechnology and medical technology sectors, including in immunology. Reacta says that he has founded and led multiple companies, raised tens of millions of dollars of funding, achieved several successful exits and delivered operational transformations as companies grow.
Among his senior leadership positions, Nagle was a strategic advisor and CEO at Immune Regulation (now Revolo Biotherapeutics and formerly Peptinnovate). In addition to his role as chair of Reacta Healthcare, he is a part-time executive director at SASPiPhi, a company developing precision antimicrobials.
Professor Ashley Woodcock, a co-founder of Reacta Healthcare and chair since inception, remains with the company in a non-executive director role.
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial